- Home
- RARE vs LBTYA Comparison
RARE vs LBTYA Comparison
Compare RARE & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- LBTYA
- Stock Information
- Founded
- RARE 2010
- LBTYA 2004
- Country
- RARE United States
- LBTYA Bermuda
- Employees
- RARE N/A
- LBTYA N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- LBTYA Cable & Other Pay Television Services
- Sector
- RARE Health Care
- LBTYA Telecommunications
- Exchange
- RARE Nasdaq
- LBTYA Nasdaq
- Market Cap
- RARE 5.2B
- LBTYA 4.2B
- IPO Year
- RARE 2014
- LBTYA N/A
- Fundamental
- Price
- RARE $40.89
- LBTYA $11.71
- Analyst Decision
- RARE Strong Buy
- LBTYA Buy
- Analyst Count
- RARE 15
- LBTYA 8
- Target Price
- RARE $92.00
- LBTYA $21.70
- AVG Volume (30 Days)
- RARE 1.0M
- LBTYA 1.8M
- Earning Date
- RARE 02-13-2025
- LBTYA 02-18-2025
- Dividend Yield
- RARE N/A
- LBTYA N/A
- EPS Growth
- RARE N/A
- LBTYA N/A
- EPS
- RARE N/A
- LBTYA N/A
- Revenue
- RARE $522,745,000.00
- LBTYA $7,674,500,000.00
- Revenue This Year
- RARE $26.70
- LBTYA $1.73
- Revenue Next Year
- RARE $19.02
- LBTYA N/A
- P/E Ratio
- RARE N/A
- LBTYA N/A
- Revenue Growth
- RARE 27.44
- LBTYA 3.53
- 52 Week Low
- RARE $37.02
- LBTYA $10.93
- 52 Week High
- RARE $60.37
- LBTYA $21.56
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- LBTYA 31.22
- Support Level
- RARE $39.99
- LBTYA $11.60
- Resistance Level
- RARE $44.52
- LBTYA $11.85
- Average True Range (ATR)
- RARE 2.18
- LBTYA 0.29
- MACD
- RARE -0.03
- LBTYA 0.02
- Stochastic Oscillator
- RARE 17.75
- LBTYA 7.59
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in several telecom companies in the UK, Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty is the owner of the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile-network-operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.